These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8519837)

  • 1. [The AIDS virus: strategies for attacking it].
    Carrasco L
    Enferm Infecc Microbiol Clin; 1995 Nov; 13(9):540-9. PubMed ID: 8519837
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral resistance and the selection of antiretroviral combinations.
    Larder BA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S28-33. PubMed ID: 8595505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of resistance to antiretroviral drugs.
    Vella S
    AIDS Clin Care; 1997 Jun; 9(6):45-7, 49, 52. PubMed ID: 11364354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
    EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent challenges and progress in AIDS therapy--emergence of drug resistant HIV-1 variants].
    Mitsuya H
    Rinsho Ketsueki; 1999 Apr; 40(4):249-54. PubMed ID: 10355129
    [No Abstract]   [Full Text] [Related]  

  • 8. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D; Karmochkine M; Si Mohamed A; Piketty C; Kazatchkine MD; Belec L
    AIDS; 1998 May; 12(7):824-5. PubMed ID: 9619820
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
    Selimova LM; Kraevskiĭ AA; Galegov GA
    Dokl Akad Nauk; 1999 Dec; 369(6):847-9. PubMed ID: 10687056
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
    J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies.
    Pérez-Alvarez L; Villahermosa ML; Cuevas MT; Delgado E; Manjón N; Vázquez de Parga E; Medrano L; Contreras G; Thomson MM; Colomo C; Taboada JA; Nájera R
    J Hum Virol; 2000; 3(3):150-6. PubMed ID: 10881995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for treating AIDS.
    Sandstrom PA; Folks TM
    Bioessays; 1996 May; 18(5):343-6. PubMed ID: 8639156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY; Johns DG; Tanaka M; Mitsuya H
    Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-drug resistant HIV-1.
    Omrani AS; Pillay D
    J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.